The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
>> Influenza has been around since the 1920’s!
Sharedealer, whilst I agree wit the sentiments expressed in your post, I need to point out that influenza has been around for a lot longer than that!!
He mentions SNG twice - first time at min 33 and for second time at about minute 42
Great find, thanks
Incredibly, Cytodyn market cap, after falling 27%, is still well north of $1billion US
Mike,
100% agree with you. This was not a randomised double blinded trial. The patient had an inhaler, and they knew it contained drug, and they felt comforted by it, and were less likely to panic and head to hospital emergency. My daughter used an inhaler like this when she was a kid. Any time she felt wheasy she would puff it. I swear I saw her get comfort from it when the damn thing was empty.
In the results published today, does it state anywhere that fewer patients were intubated, or fewer patients went into ICU as a result of taking Budesonide? No. End of story for me.
SYNGold - just to add that VIR is up 45-50% on opening in the US. This means it has just added $2.5 Billion to its market cap. And VIR shares the drug with GSK I think ;-)
Thanks syngold, great post
Shares of Paris-based Abivax SA (Paris:ABVX) fell 25.4% to €21 (US$25.07) on March 8 after the company said it would halt a phase IIb/III trial of its lead candidate, ABX-464, in high-risk COVID-19 patients for lack of efficacy.
Scinv, US company Northwest Bio NWBO is running a p3 trial for the past 12 years and has a market cap of 1.5bn. Complete junk compared to SG
Meelie, what makes that list worse is that South Dakota population is 90% white. Their death rate should be a lot lower than states with significant black/hispanic population. Tragic outcome for many there
gbk - perhaps outright fail is too strong a term to use, but when the DSMB suggest that "sensitivity analyses of the available data raised concerns about the magnitude of potential benefit" - all I can see is the company putting a spin on a failed trial.
Yet another COVD treatment fails. Who will be the last man standing?
Shares of Vir Biotechnology Inc. VIR, tumbled 5.4% in premarket trading on Thursday, the day after the company said the experimental COVID-19 treatment that it's developing with GlaxoSmithKline GSK, may not benefit patients. The investigational monoclonal antibody therapy was being tested in hospitalized COVID-19 patients in a Phase 3 clinical trial conducted by the National Institutes of Health until an independent safety board recommended that the trial investigators close the study to enrollment at this time, Vir said. "While we are disappointed with the recommendation ... we are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients," Vir CEO George Scangos said in a news release.
100% agree Doc, the science that demonstrates the benefits of wearing masks has long been settled.
Kevin,
The same guy was promising deals with India several weeks ago and then news a few days ago. Eventually, just like a stopped clock, he will time it right and claim glory. Treat these guys just like you treat any ramper/deramper. Instead focus on the science and what we do know.
Thanks HarChris,
As you point out, I was not gloating. I was simply stating a fact.
Another competitor falls flat on its face
Shares of GlaxoSmithKline were down 0.2% in trading on Thursday after the drug maker said its experimental monoclonal antibody treatment did not meet the primary endpoint in a mid-stage trial evaluating its use in hospitalized COVID-19 patients of all age groups. As part of the study's design, the therapy, otilimab, was given in addition to the standard of care, which includes treatments such as Gilead Sciences Inc.'s antiviral Veklury. GSK said it will now refocus the study on patients older than 70 years old, with plans to enroll 350 people who fit this demographic, after data from that study indicated the antibody treatment was more likely to improve outcomes for older patients. GSK said it plans to publish the details of the initial Phase 2 trial in a preprint.
>> RECOVERY trials seem more like a cunning stunt to me...
I misread that as... "RECOVERY trials seem more like a stunning c**t to me"
Amazing, the other treatments are delayed , SNG has the trial all to itself. Every enrolled patient will be on a nebuliser. Hopefully we get a week or two headstart before the others join.
>> "the nebullised treatment has a very specific list of people
>> who might be excluded" Is SNG poorly tolerated by anyone ?
Doc, is it possible that the SNG001 treatment is only for those who
have those known genetic predisposition to severe disease. ie they
have genetic weakness in terms of producing an interferon response
to the initial infection by the virus.
In a way I hope this is the case as I think SNG001 would blow the
lid off the trial - but it would also limit the potential population
eligible for treatment
>> At the very least the British government should be thinking of
>> putting in order with sng before the yanks do, the cost of the
>> yanks getting first dips will be humiliation for the world to see.
You are 100% right. The UK home trial results will be known imminently. Boris and co will then know that they can either wait, and let the US steal their thunder, or act immediately and claim the glory for the UK. I think this will explode in matter of days before the end of this month.